The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
Open accessPublished version of a preprint
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The proportion of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can be detected up to 3 months after symptom resolution. We investigated both seroconversion and PCR positivity in a large cohort of convalescent serum donors in the New York City (NY, USA) region. METHODS: In this observational study, we ran an outreach programme in the New York City area. We recruited participants via the REDCap (Vanderbilt University, Nashville, TN, USA) online survey response. Individuals with confirmed or suspected SARS-CoV-2 infection were screened via PCR for presence of viral genome and via ELISA for presence of anti-SARS-CoV-2 spike antibodies. One-way ANOVA and Fisher's exact test were used to measure the association of age, gender, symptom duration, and days from symptom onset and resolution with positive antibody results. FINDINGS: Between March 26 and April 10, 2020, we measured SARS-CoV-2 antibody titres in 1343 people. Of the 624 participants with confirmed SARS-CoV-2 infection who had serologies done after 4 weeks, all but three seroconverted to the SARS-CoV-2 spike protein, whereas 269 (37%) of 719 participants with suspected SARS-CoV-2 infection seroconverted. PCR positivity was detected up to 28 days from symptom resolution. INTERPRETATION: Most patients with confirmed COVID-19 seroconvert, potentially providing immunity to reinfection. We also report that in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks after symptom resolution, but it is unclear whether this signal represents infectious virus. Analysis of our large cohort suggests that most patients with mild COVID-19 seroconvert 4 weeks after illness, and raises questions about the use of PCR to clear positive individuals. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Self-citationRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Self-citation
Research works printed but not linked: 18
- Chang, 2020, Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection, Am J Respir Crit Care Med, 201, 1150, 10.1164/rccm.202003-0524LE · DOI · Paper page
- Lan, 2020, Positive RT-PCR test results in patients recovered from COVID-19, JAMA, 323, 10.1001/jama.2020.2783 · DOI · Paper page
- Xiao, 2020, Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients, Clin Infect Dis, 10.1093/cid/ciaa460 · DOI · Paper page
- Chu, 2005, Duration of RT-PCR positivity in severe acute respiratory syndrome, Eur Respir J, 25, 12, 10.1183/09031936.04.00057804 · DOI
- Wu, 2020, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, medRxiv
- Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci USA, 117, 9490, 10.1073/pnas.2004168117 · DOI · Paper page
- Bloch, 2020, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J Clin Invest, 130, 2757, 10.1172/JCI138745 · DOI · Paper page
- Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, 323, 10.1001/jama.2020.4783 · DOI · Paper page
- Stadlbauer, 2020, SARS-CoV-2 Seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup, Curr Protoc Microbiol, 57, e100, 10.1002/cpmc.100 · DOI · Paper page
- Pujadas, 2020, Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test, J Med Virol, 92, 1695, 10.1002/jmv.25988 · doi:10.1002/jmv.25988
- Moran, 2020, Detection of SARS-CoV-2 by use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays, J Clin Microbiol, 58, e00772, 10.1128/JCM.00772-20 · DOI
- Broder, 2020, Test agreement between Roche cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 assays at high cycle threshold ranges, J Clin Microbiol, 58, e01187, 10.1128/JCM.01187-20 · DOI
- Craney, 2020, Comparison of two high-throughput reverse transcription-polymerase chain reaction systems for the detection of severe acute respiratory syndrome coronavirus 2, J Clin Microbiol, 58, e00890, 10.1128/JCM.00890-20 · doi:10.1128/jcm.00890-20
- Wajnberg, 2020, SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months, medRxiv
- Cao, 2007, Disappearance of antibodies to SARS-associated coronavirus after recovery, N Engl J Med, 357, 1162, 10.1056/NEJMc070348 · DOI · Paper page
- Al-Abdely, 2019, Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia, Emerg Infect Dis, 25, 753, 10.3201/eid2504.181595 · DOI
- Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease, medRxiv
- Lin, 2012, Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics, Proc Natl Acad Sci USA, 109, 14989, 10.1073/pnas.1211138109 · DOI
Cited by
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Self-citationPreexisting and de novo humoral immunity to SARS-CoV-2 in humans
Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A. G., Benton, D. J., et al. (2020) · Science · doi:10.1126/science.abe1107 · Cited by 886
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study
Iversen, K., Bundgaard, H., Hasselbalch, R. B., Kristensen, J. H., Nielsen, P. B., Pries-Heje, M., Knudsen, A. D., Christensen, C. E., Fogh, K., Norsk, J. B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30589-2 · Cited by 431
La Marca, A., Capuzzo, M., Paglia, T., Roli, L., Trenti, T., & Nelson, S. M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.06.001 · Cited by 389
Metadata
- Authors
- Wajnberg, A., Mansour, M., Leven, E., Bouvier, N. M., Patel, G., Firpo-Betancourt, A., Mendu, R., Jhang, J., Arinsburg, S., Gitman, M., Houldsworth, J., Sordillo, E., Paniz-Mondolfi, A., Baine, I., Simon, V., Aberg, J., Krammer, F., Reich, D., & Cordon-Cardo, C.
- Venue
- The Lancet Microbe
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 1
- Issue
- 7
- Pages
- e283-e289
- ISSN
- 2666-5247 (ISSN-L)
- OpenAlex
- W3088674565
- Cited by
- 222
- References
- 2
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. https://app.cochat.ai/papers/10.1016/s2666-5247(20)30120-8
- The paper
- Wajnberg, A., Mansour, M., Leven, E., Bouvier, N. M., Patel, G., Firpo-Betancourt, A., Mendu, R., Jhang, J., Arinsburg, S., Gitman, M., Houldsworth, J., Sordillo, E., Paniz-Mondolfi, A., Baine, I., Simon, V., Aberg, J., Krammer, F., Reich, D., & Cordon-Cardo, C. (2020). Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(20)30120-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.